February 28, 2021
Article
Late-breaking data show allegic children as young as 1-4 years old may have sustained benefit from daily peanut protein exposure.
An interview with a Children's Hospital Colorado investigator on new remote-monitoring research into children's adherence trends.
Trials testing hydroxychloroquine against COVID-19 have produced mixed results.
The adjusted allergy prevalence in recent years was 2.6% in infants who have been introduced to peanuts at 12 months.
February 27, 2021
Video
A nNew survey results depict unexpected burdens in long-haul patients, as well as continued issues following rehabilitatio provides insight into long-term COVID-19 symptoms and complications unresolved from rehabilitation.n.
Common positive effects includes help with sleep, less pain, and calming influence.
An interview with a study author on new interpretations of biologic asthma benefit.
A discussion on continued research into the first regulated treatment for pediatric peanut allergy.
Treatment showed a similar effect on patients with and without baseline asthma.
February 26, 2021
All patients in the study who tested positive for COVID-19 suffered from mild or moderate symptoms.
